

Indian Council of Medical Research (ICMR), New Delhi
Expression of Interest (EoI) for
Contributing Data from Existing Indian Cohorts to Indo-US Collaborative Research
focused on Heterogeneity of Diabetes to Enable Precision Diabetes

1. Background

Under the ICMR-NIDDK Joint [Implementing Agreement on Diabetes Research](#)., it is proposed to fund joint diabetes research studies leveraging existing cohorts in both countries, i.e., India and US. In this context, there is a need to identify suitable cohorts in India that have relevant clinical, metabolic, and longitudinal variables and are willing to participate in Indo-US collaborative research.

This collaboration aims to advance scientific understanding of diabetes, particularly its marked **heterogeneity** across individuals and populations—manifested in differences in disease subtypes, progression, treatment response, and complications—to enable ‘**precision diabetes**’ approaches, with joint funding support from ICMR and NIDDK as per the agreed framework.

2. Invitation for Expression of Interest

ICMR invites Expression of Interest (EoI) from investigators in India for the identification of existing cohorts relevant to diabetes and related metabolic disorders. This EoI seeks to identify cohorts that possess key clinical and phenotypic variables and whose investigators are willing to participate in joint Indo-US collaborative research studies by contributing existing data.

Investigators submitting an EoI should be willing to collaborate under this framework and consent to sharing the information provided in the EoI with ICMR and NIDDK and associated Indian and U.S. collaborators for the purpose of cohort selection, harmonization, and development of joint research proposals.

3. Modality for Submission of Expression of Interest

Interested investigators/institutions are required to submit the duly filled **Annexure I** along with a **brief note** (maximum 1 page) describing the cohort, its relevance to the objectives of the Indo-US collaboration, and motivation/interest for participation in joint research. The documents should be submitted via email to indousniddk2026@gmail.com on or before **15th July 2026**.

Cohorts with adequate sample size, availability of key clinical and longitudinal variables, and suitability for harmonized analyses will be shortlisted. Shortlisted investigators may be invited for further discussions, including participation in a joint protocol development workshop with ICMR and NIDDK counterparts.

4. Role of ICMR

ICMR will review the EoIs, identify suitable cohorts, facilitate interactions between Indian and U.S. investigators for harmonization and development of joint research proposals, and coordinate subsequent scientific and administrative processes in alignment with the Indo-US agreement.

5. Disclaimer

ICMR reserves the right to accept or reject any or all submissions, or to modify or withdraw this EoI, without assigning any reason.

6. Contact

For any clarifications related to this EoI, kindly send an email on indousniddk2026@gmail.com or contact:

Dr. Tanvir Kaur Gandhi

Scientist G and Head, International Health Division

Indian Council of Medical Research, New Delhi

Email: headihd.hq@icmr.gov.in

Annexure I

Proforma for Submission of Details of Existing Cohorts under Expression of Interest (EoI)

(To be filled by the Principal Investigator)

1. Details of Principal Investigator and Team

Name of Principal Investigator (PI):

Designation:

Institution/Organisation:

Department/Division:

Email ID and Contact Number:

Names of Co-Investigator(s) and Affiliations (if any):

Please provide CV of the PI and other key investigators. Each CV should include

- Academic and professional qualifications
- Current position and affiliation
- Up to five most relevant previous research grants
- Upto five most relevant previous publications
- H-index

2. Details of the Cohort

Name of the Cohort:

Institution/Centre responsible for the Cohort:

Geographic location (City/State/Region):

Type of Cohort (please tick):

Clinic-based Population-based (Epidemiological)

If clinic-based, indicate approximate percentage of drug-naïve participants: _____

Whether the cohort was Cross sectional or Longitudinal? _____

If Cross sectional, the year when data collection was completed: _____

If Longitudinal, how many years of follow up is available: _____ years

Brief description of the study population (e.g., urban/rural, hospital-based, community-based, etc.):

Whether the cohort has been used in prior studies: Yes No

If yes, briefly provide details (including any publications): _____

3. Cohort Characteristics

Total cohort size: _____

Number of participants with Type 2 Diabetes Mellitus (T2DM): _____

Demographic details available (please tick):

Age: Yes No

Sex: Yes No

4. Availability of Clinical and Metabolic Variables

(Please indicate availability as Yes/No and provide details where applicable)

	Variable	Available (Yes/No)	Details (if applicable)
Mandatory Variables:			
1.	Age at onset of diabetes		
2.	Duration of diabetes		
3.	Medication history		
4.	Body weight		
5.	Body Mass Index (BMI)		
6.	Waist circumference		
7.	Fasting plasma glucose		
8.	Oral Glucose Tolerance Test		
9.	HbA1c		
10.	Lipid profile (LDL, HDL, TG, Total Cholesterol etc.)		
11.	Kidney function (eGFR/Creatinine/Cystatin C etc.)		
12.	Liver function test SGOT/SGPT & Gamma GT		
13.	Treatment-related Data (such as oral hypoglycemic agents, insulin therapy, combination therapy, and drug-naïve status)		
Optional Variables:			
14.	HOMA- IR		
15.	HOMA2 beta-cell function		
16.	HOMA2-IR		
17.	TG to glucose index		
18.	Complications-related data (nephropathy, retinopathy, neuropathy, myocardial infarction, stroke, etc.)		
19.	Any biological samples/biospecimens available (e.g., serum, plasma, DNA, saliva/urine samples etc.)		

5. Declaration

I hereby confirm that the information provided above is accurate to the best of my knowledge. I consent to sharing the information submitted under this EoI with ICMR and NIDDK, and associated collaborators for the purpose of cohort selection. If shortlisted, I am willing to participate in development of joint research proposals and the Indo-US collaborative research framework.

Name of Principal Investigator:

Signature:

Date: